View Older Stories View More Recent Stories
-
Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 11c; lifts outlook
-
Bristol Myers Squibb shows long-term Sotyktu efficacy data
-
Evotec receives $25 million from Bristol Myers Squibb for neuroscience work
-
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
-
SystImmune and Bristol Myers Squibb report phase I trial results for cancer drug
-
insitro extends Bristol Myers Squibb collaboration for ALS drug discovery
-
Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion
-
Bristol-Myers Squibb (BMY) call put ratio 3.9 calls to 1 put with a focus on a spreader of 10K contracts of November 48 and 52.50 calls
-
BMS-986446 receives FDA fast track designation for alzheimer's treatment
-
CFRA Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Bristol Myers Squibb gets FDA fast track for alzheimer's drug candidate
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Bristol Myers Squibb expands direct-to-patient drug sales program
-
Stifel on Veeva Systems (VEEV): 'today's announcement is not incremental'
-
Bristol-Myers Squibb (BMY) to sell its new schizophrenia treatment in the UK for $22,500/yr, same price as in the U.S. - FT
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Bristol Myers Squibb presents real-world Camzyos data at ESC Congress
-
FDA grants breakthrough therapy status to Bristol Myers lung cancer drug
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Cantor Fitzgerald
-
FDA accepts Bristol Myers Squibb's Breyanzi application for fifth cancer type
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance
-
Bristol-Myers Squibb (BMY) call put ratio 1.2 calls to 1 put into quarter results
-
Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb and Bain Capital form immunology company with $300M
-
Bristol Myers Squibb gets FDA review for psoriatic arthritis drug
-
Raymond James Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea
-
Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
-
Bristol-Myers Squibb (BMY) call put ratio 2.5 calls to 1 put with a focus on August calls
-
UBS Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
FDA removing REMS from several CAR-T cell therapies positive for these 3 stocks - William Blair
-
Bristol-Myers Squibb (BMY) Declares $0.62 Quarterly Dividend; 5.3% Yield
-
Bristol-Myers Squibb (BMY) Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial
-
Cantor Fitzgerald Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader
-
Bristol-Myers Squibb (BMY) Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial
-
Philogen subsidiary and Bristol-Myers (BMY) subsidiary announce licensing agreement for OncoACP3
-
Any near-term weakness in S&P 500 would provide a 'buy the dip' opportunity: JPM
-
Raymond James Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
JPMorgan Reiterates Neutral Rating on BioNTech (BNTX)
-
Citi on Bristol-Myers Squibb Co. (BMY): 'ASCO 2025: Early stage ADCs support breadth of oncology portfolio'
-
BioNTech soars 15% on cancer drug deal with Bristol Myers
-
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration
-
Bristol-Myers Squibb (BMY) and Biontech (BNTX) enter up to $11.1B Cancer Deal
